Murinized Anti-mouse PD-1 Antibody (RMP1-14.1) | PA007162.mm2a

$595.00

Recombinant mouse anti-mouse PD 1 / CD279 monoclonal antibodies, whose variable region sequences are murined from the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14), are produced from mammalian cells. The recombinant rat and chimeric mouse versions of the RMP1-14 antibody are also available.

Details & Specifications
References

Catalog No.	PA007162.mm2a
Product Name	In Vivo Grade Recombinant Murinized Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a Kappa
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Mouse Anti-Mouse PD 1 Monoclonal Antibodies, Murinized Anti-Mouse PD 1 Monoclonal Antibodies
Summary	The In Vivo Grade Recombinant Murinized Anti-mouse PD-1 Mouse IgG2a Kappa Monoclonal Antibody (Clone RMP1-14.1) was produced in mammalian cells.
Clone	RMP1-14.1, the murinized variable region sequences of the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14)
Applications	immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Immunogen	The original rat hybridoma (clone name: RMP1-14) was generated by immunizing Sprague Dawley rats with mouse PD-1-transfected BHK cells and using a P3U1 myeloma as the fusion partner.
Form Of Antibody	0.2 μM filtered solution of 1x PBS.
Endotoxin	Less than 1 EU/mg of protein as determined by LAL method.
Purity	>95% by SDS-PAGE under reducing conditions.
Shipping	The In Vivo Grade Recombinant Murinized Anti-mouse PD-1 Mouse IgG2a Kappa Monoclonal Antibody (Clone RMP1-14.1) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 1 month from date of receipt, 2 to 8°C as supplied. 3 months from date of receipt, -20°C to -70°C as supplied.
Note	Recombinant mouse anti-mouse PD 1 / CD279 monoclonal antibodies, whose variable region sequences are murined from the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14), are produced from mammalian cells. The recombinant rat and chimeric mouse versions of the RMP1-14 antibody are also available.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007162.mm2a: Recombinant Murinized Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a, kappa, In Vivo Grade
The in vivo grade recombinant murinized rat anti-mouse PD-1 monoclonal antibody (mouse IgG2c-LALAPG kappa) was produced in mammalian cells.

References of Anti-mouse PD-1 Monoclonal Antibody (Clone: RMP1-14)

1. PD-L1/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior.
Fan, et al.J Neuroinflammation. 2023 Sep 25;20(1):222. PMID: 37759247; PMCID: PMC10529885
“We found that PD-1 expression was significantly increased in the hippocampus of chronic unpredictable mild stress (CUMS) mice. PD-1 deficiency or blockade of the PD-1/PD-L1 pathway with the RMP1-14 antibody improved depressive-like behaviors and cognitive deficits in CUMS mice. Furthermore, we demonstrated that the PD-1/PD-L1 pathway regulates neuronal excitability and synaptic plasticity in the hippocampus.”

2. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration.
Li, et al.Nat Commun. 2022 Apr 19;13(1):2062. PMID: 35439798; PMCID: PMC9023578
“We show that PD-L1 is highly expressed on lymphatic endothelial cells (LECs) and its engagement by PD-1 on T cells regulates T cell migration. Blocking PD-1/PD-L1 interaction using RMP1-14 antibody in vivo increased T cell retention in lymph nodes. This mechanism provides a previously uncharacterized pathway for the regulation of T cell trafficking during immune responses.”

3. Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain.
Koyama, et al.Cancer Immunol Res. 2021 Sep;9(9):1042-1052. PMID: 34187834; PMCID: PMC8391891
“We identified that macrophages are the main cells that interact with the Fc domain of anti-PD-1 antibodies. Interaction of the anti-PD-1 antibody (clone RMP1-14) Fc domain with macrophage Fc receptors impaired the antitumor activity of TLR9 agonists. Modifying the Fc domain to prevent this interaction restored the antitumor efficacy of the combination therapy.”

4. Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
McGuire, et al.Cell Rep Med. 2024 Aug 20;5(8):101668. PMID: 39097722; PMCID: PMC11293404
“Dual checkpoint blockade (anti-CTLA-4 and anti-PD-1) is highly effective but associated with significant immune-related adverse events. We investigated the role of IL-23 in the toxicity of dual checkpoint blockade. Treatment with RMP1-14 (anti-PD-1) and anti-CTLA-4 triggered severe colitis, which was prevented by prophylactic IL-23 blockade without compromising antitumor immunity.”

5. Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy.
Wang, et al.Cancer Med. 2023 May;12(9):10636-10648. PMID: 37158784; PMCID: PMC10166916
“Combining anti-angiogenic agents with immune checkpoint inhibitors has shown potential in cancer treatment. We evaluated whether pre-administration of an angiogenic inhibitor improves the efficacy of anti-PD-1 (RMP1-14) antibody treatment. The results indicated that normalized vascularization facilitated T cell infiltration and significantly enhanced the therapeutic outcomes of immunotherapy.”

For more technical references or data sheets regarding the Anti-mouse PD-1 Monoclonal Antibody (Clone: RMP1-14) formats, please contact our scientific support team at message@sydlabs.com.